Evaluating 5-nitrofurans as trypanocidal agents

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1638-1647

  Bot, Christopher ^a,c   Hall, Belinda S ^a,d   Álvarez, Guzmán ^b   Di Maio, Rossanna ^b   González, Mercedes ^b   Cerecetto, Hugo ^b   Wilkinsona, Shane R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; CARBAZATE DERIVATIVE; EFLORNITHINE; NIFURTIMOX; NITROFURAL DERIVATIVE; NITROREDUCTASE; SEMICARBAZONE DERIVATIVE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; BLOODSTREAM INFECTION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; GENE OVEREXPRESSION; IC 50; IN VITRO STUDY; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRYPANOSOMA BRUCEI;

NITROFURANS; NITROREDUCTASES; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI;

EID: 84875127098     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02046-12     Document Type: Article

References (48)

1. Barrett MP. 1999. The fall and rise of sleeping sickness. Lancet 353:1113-1114.
2. Brun R, Blum J, Chappuis F, Burri C. 2010. Human African trypanosomiasis. Lancet 375:148 -159.
3. Wilkinson SR, Kelly JM. 2009. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev. Mol. Med. 11:e31. doi: 10.1017/S1462399409001252.
4. Matovu E, Geiser F, Schneider V, Mäser P, Enyaru JC, Kaminsky R, Gallati S, Seebeck T. 2001. Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Mol. Biochem. Parasitol. 117:73- 81.
5. Brun R, Schumacher R, Schmid C, Kunz C, Burri C. 2001. The phenomenon of treatment failures in Human African trypanosomiasis. Trop. Med. Int. Health 6:906 -914.
6. Dodd MC. 1946. The chemotherapeutic properties of 5-nitro-2-furaldehyde semicarbazone (Furacin). J. Pharmacol. Exp. Ther. 86:311-323.
7. Evens F, Niemegeers K, Packchanian A. 1957. Nitrofurazone therapy of Trypanosoma gambiense sleeping sickness in man. Am. J. Trop. Med. Hyg. 6:665- 678.
8. Packchanian A. 1955. Chemotherapy of African sleeping sickness. I. Chemotherapy of experimental Trypanosoma gambiense infection in mice (Mus musculus) with nitrofurazone. Am. J. Trop. Med. Hyg. 4:705-711.
9. Bock M, Gönnert R, Haberkorn A. 1969. Studies with Bay 2502 on animals. Bol. Chil. Parasitol. 24:13-19.
10. Jannin J, Villa L. 2007. An overview of Chagas disease treatment. Mem. Inst. Oswaldo Cruz 102(Suppl 1):95-97.
11. Yun O, Priotto G, Tong J, Flevaud L, Chappuis F. 2010. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl. Trop. Dis. 4:e720. doi: 10.1371/journal.pntd. 0000720.
12. Saulnier Sholler GL, Kalkunte S, Greenlaw C, McCarten K, Forman E. 2006. Antitumor activity of nifurtimox observed in a patient with neuroblastoma. J. Pediatr. Hematol. Oncol. 28:693- 695.
13. Peterson FJ, Mason RP, Hovsepian J, Holtzman JL. 1979. Oxygensensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. J. Biol. Chem. 254:4009-4014.
14. Mason RP, Holtzman JL. 1975. The mechanism of microsomal and mitochondrial nitroreductase. Electron spin resonance evidence for nitroaromatic free radical intermediates. Biochemistry 14:1626 -1632.
15. Mason RP, Holtzman JL. 1975. The role of catalytic superoxide formation in the O2 inhibition of nitroreductase. Biochem. Biophys. Res. Commun. 67:1267-1274.
16. Docampo R, Moreno SN, Stoppani AO, Leon W, Cruz FS, Villalta F, Muniz RF. 1981. Mechanism of nifurtimox toxicity in different forms of Trypanosoma cruzi. Biochem. Pharmacol. 30:1947-1951.
17. Docampo R, Stoppani AO. 1979. Generation of superoxide anion and hydrogen peroxide induced by nifurtimox in Trypanosoma cruzi. Arch. Biochem. Biophys. 197:317-321.
18. Henderson GB, Ulrich P, Fairlamb AH, Rosenberg I, Pereira M, Sela M, Cerami A. 1988. "Subversive" substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. Proc. Natl. Acad. Sci. U. S. A. 85:5374 -5378.
19. Viodé C, Bettache N, Cenas N, Krauth-Siegel RL, Chauvière G, Bakalara N, Péri é J. 1999. Enzymatic reduction studies of nitroheterocycles. Biochem. Pharmacol. 57:549 -557.
20. Blumenstiel K, Schöneck R, Yardley V, Croft SL, Krauth-Siegel RL. 1999. Nitrofuran drugs as common subversive substrates of Trypanosoma cruzi lipoamide dehydrogenase and trypanothione reductase. Biochem. Pharmacol. 58:1791-1799.
21. Boveris A, Sies H, Martino EE, Docampo R, Turrens JF, Stoppani AO. 1980. Deficient metabolic utilization of hydrogen peroxide in Trypanosoma cruzi. Biochem. J. 188:643- 648.
22. Temperton NJ, Wilkinson SR, Meyer DJ, Kelly JM. 1998. Overexpression of superoxide dismutase in Trypanosoma cruzi results in increased sensitivity to the trypanocidal agents gentian violet and benznidazole. Mol. Biochem. Parasitol. 96:167-176.
23. Prathalingham SR, Wilkinson SR, Horn D, Kelly JM. 2007. Deletion of the Trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole. Antimicrob. Agents Chemother. 51:755-758.
24. Kelly JM, Taylor MC, Smith K, Hunter KJ, Fairlamb AH. 1993. Phenotype of recombinant Leishmania donovani and Trypanosoma cruzi which over-express trypanothione reductase. Sensitivity towards agents that are thought to induce oxidative stress. Eur. J. Biochem. 218:29 -37.
25. Hall BS, Bot C, Wilkinson SR. 2011. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 286:13088 -13095.
26. Pal D, Banerjee S, Cui J, Schwartz A, Ghosh SK, Samuelson J. 2009. Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob. Agents Chemother. 53:458-464.
27. Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. 2008. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. U. S. A. 105:5022-5027.
28. Hall BS, Wilkinson SR. 2012. Activation of benznidazole by trypano-somal type I nitroreductases results in glyoxal formation. Antimicrob. Agents Chemother. 56:115-123.
29. Baker N, Alsford S, Horn D. 2011. Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6. Mol. Biochem. Parasitol. 176:55-57.
30. Alsford S, Eckert S, Baker N, Glover L, Sanchez-Flores A, Leung KF, Turner DJ, Field MC, Berriman M, Horn D. 2012. High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 482: 232-236.
31. Gavin JJ, Ebetino FF, Freedman R, Waterbury WE. 1966. The aerobic degradation of 1-(5-nitrofurfurylideneamino)-2-imidazolidinone (NF-246) by Escherichia coli. Arch. Biochem. Biophys. 113:399-404.
32. Kubata BK, Kabututu Z, Nozaki T, Munday CJ, Fukuzumi S, Ohkubo K, Lazarus M, Maruyama T, Martin SK, Duszenko M, Urade Y. 2002. A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi. J. Exp. Med. 196:1241-1251.
33. Gerpe A, Alvarez G, Benítez D, Boiani L, Quiroga M, Hernández P, Sortino M, Zacchino S, González M, Cerecetto H. 2009. 5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene. Bioorg. Med. Chem. 17:7500 -7509.
34. Gerpe A, Odreman-Nuñez I, Draper P, Boiani L, Urbina JA, González M, Cerecetto H. 2008. Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action. Bioorg. Med. Chem. 16:569 -577.
35. Aguirre G, Cabrera E, Cerecetto H, Di Maio R, Gonzalez M, Seoane G, Duffaut A, Denicola A, Gil MJ, Martinez-Merino V. 2004. Design, synthesis and biological evaluation of new potent 5-nitrofuryl derivatives as anti-Trypanosoma cruzi agents. Studies of trypanothione binding site of trypanothione reductase as target for rational design. Eur. J. Med. Chem. 39:421- 431.
36. Aguirre G, Boiani L, Cerecetto H, Fernandez M, Gonzalez M, Denicola A, Otero L, Gambino D, Rigol C, Olea-Azar C, Faundez M. 2004. In vitro activity and mechanism of action against the protozoan parasite Trypanosoma cruzi of 5-nitrofuryl containing thiosemicarbazones. Bioorg. Med. Chem. 12:4885- 4893.
37. Hirumi H, Hirumi K. 1989. Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J. Parasitol. 75:985-989.
38. Alsford S, Kawahara T, Glover L, Horn D. 2005. Tagging a T. brucei RRNA locus improves stable transfection efficiency and circumvents inducible expression position effects. Mol. Biochem. Parasitol. 144:142-148.
39. Portal P, Villamil SF, Alonso GD, De Vas MG, Flawia MM, Torres HN, Paveto C. 2008. Multiple NADPH-cytochrome P450 reductases from Trypanosoma cruzi suggested role on drug resistance. Mol. Biochem. Parasitol. 160:42-51.
40. Jones DC, Hallyburton I, Stojanovski L, Read KD, Frearson JA, Fairlamb AH. 2010. Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochem. Pharmacol. 80:1478 -1486.
41. Hall BS, Wu X, Hu L, Wilkinson SR. 2010. Exploiting the drugactivating properties of a novel trypanosomal nitroreductase. Antimicrob. Agents Chemother. 54:1193-1199.
42. Bot C, Hall BS, Bashir N, Taylor MC, Helsby NA, Wilkinson SR. 2010. Trypanocidal activity of aziridinyl nitrobenzamide prodrugs. Antimicrob. Agents Chemother. 54:4246-4252.
43. McCalla DR. 1983. Mutagenicity of nitrofuran derivatives: review. Environ. Mutagen. 5:745-765.
44. Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, Brun R, Mazue G, Bray MA, Pecoul B. 2010. Fexinidazole - a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl. Trop. Dis. 4:e923. doi: 10.1371/journal.pntd.0000923.
45. Coppens I, Courtoy PJ. 2000. The adaptative mechanisms of Trypanosoma brucei for sterol homeostasis in its different life-cycle environments. Annu. Rev. Microbiol. 54:129 -156.
46. Sokolova AY, Wyllie S, Patterson S, Oza SL, Read KD, Fairlamb AH. 2010. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob. Agents Chemother. 54: 2893-2900.
47. Rao DN, Harman L, Motten A, Schreiber J, Mason RP. 1987. Generation of radical anions of nitrofurantoin, misonidazole, and metronidazole by ascorbate. Arch. Biochem. Biophys. 255:419-427.
48. Rao DN, Mason RP. 1987. Generation of nitro radical anions of some 5-nitrofurans, 2- and 5-nitroimidazoles by norepinephrine, dopamine, and serotonin. A possible mechanism for neurotoxicity caused by nitroheterocyclic drugs. J. Biol. Chem. 262:11731-11736.